What is Nsos?
Nsos operates at the intersection of neurology and immunology, developing a sophisticated platform designed to restore neurological pathways that govern immune responses. By utilizing engineered electrical signals delivered via a noninvasive interface, the company aims to address complex disease states that have historically proven resistant to traditional pharmacological interventions. The organization maintains a robust research ecosystem, leveraging deep scientific collaborations with elite academic institutions such as Stanford, Harvard, and the University of California, San Francisco. This collaborative framework ensures that Nsos remains at the vanguard of bioelectronic medicine, bridging the gap between fundamental neuroscience and scalable therapeutic applications.
How much funding has Nsos raised?
Nsos has raised a total of $16.5M across 1 funding round:
Unspecified
$16.5M
Unspecified (2020): $16.5M with participation from Mayfield
Key Investors in Nsos
Mayfield
Mayfield is a Menlo Park-based venture capital firm that raises dedicated funds to invest in early-stage technology companies, primarily at seed and Series A, backing enterprise, consumer, and infrastructure founders and partnering with them through growth and exit.
What's next for Nsos?
The infusion of capital will likely accelerate the transition from experimental research to rigorous clinical trials. As Nsos scales its operations, the strategic focus will shift toward refining its signal-processing algorithms and expanding its intellectual property portfolio. Given the enterprise-level nature of this funding, the company is expected to prioritize the development of regulatory-compliant manufacturing processes and the expansion of its clinical advisory board. By maintaining its commitment to rigorous scientific inquiry, Nsos is poised to redefine the standard of care for immune-mediated disorders, potentially establishing a new category of therapeutic intervention that leverages the body's own electrical circuitry to achieve systemic health outcomes.
See full Nsos company page
